Millennial & Gen X Moms Struggle with the Mental Load, Spending a Staggering 520 Hours Per Year on Invisible Labor   •   Coursera Announces Four New Entry-Level Certificates from Microsoft to Help Learners Pursue High-demand Jobs   •   Jeepers Go Topless to Raise Money for Charity   •   VinciVR, New York Offshore Wind Developers, and NYC Colleges launch Immersive Education Week for Wind Careers   •   ANU - Museum of the Jewish People in Tel Aviv, Israel Receives $1.5 Million from the Mike and Sofia Segal Foundation   •   4 Organizations Partner to Champion Safe Sleep for Babies   •   Butterfly Kisses Ultrasound Imaging Center Opens its Doors in Swedesboro, NJ!   •   Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting   •   Animal Alerts powered by PetPace™ Turns Pet Health Data into Earthquake Warnings   •   Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)   •   Bumble Inc. Signs Agreement to Acquire Group and Community App Geneva   •   NEW YORK'S ONLY OUTPATIENT PROGRAM FOR REDUCING ALLERGIC REACTIONS TO CANCER TREATMENTS HITS NEW CARE MILESTONE   •   This Father’s Day, Staples Is Helping Dads ‘Cut the Cord’ With Their Box of Old Cables to Create the First-of-   •   American Camp Association Awarded $2.25 Million to Create, Improve, and Expand Leadership Pathways at Camp for Young People of D   •   MetLife Launches My Leave Navigator to Support Employees Navigating Leave   •   IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Health   •   Ameresco Awarded $21 Million Contract to Illuminate Henderson's Streets with State-of-the-Art LED Technology   •   Operation Homefront Receives National Recognition for Impact and Innovation Campaigns   •   Electrosoft CEO Dr. Sarbari Gupta Honored with 2024 WIT Leadership Award   •   Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics’ COV